The case for & against
Bull & Bear analysis
Alphatec Holdings, Inc. (NASDAQ: ATEC) is an emerging player in the advanced spinal technologies sector, focusing on innovative solutions designed to improve surgical outcomes and foster enhanced surgeon adoption. The company is dedicated to developing proprietary technologies, notably the EOS system, that enhance procedural efficacy and overall patient care. With a recent emphasis on expanding its market presence through strategic surgeon engagement, ATEC is capitalizing on the growth trend within the spine surgery market, positioning itself as a key competitor amid ongoing industry advancement.
Bull says
- ↑Q2 revenue of $214M (+15% YoY), surgical revenue $196M (+17%).
- ↑Surgical cases +20% and new surgeon adoption +24% drive growth.
- ↑Adjusted EBITDA $36M (+53% YoY) with margin expansion to 17%.
- ↑International expansion in Japan and Australia supports market penetration.
- ↑Generated $1M FCF; projecting $4–6M FCF in Q3 2026.
- ↑Strong growth and positive earnings yield factors with healthy liquidity.
Bear says
- ↓Profitability score negative; EPS misses indicate shaky profit model.
- ↓Stagnant biologics attachment rates may limit future revenue growth.
- ↓Momentum score negative and $33M capex elevates cash flow risk.
- ↓Intense competition from established players could erode market share.
- ↓Weak book-to-price and dividend yield factors suggest valuation concerns.
- ↓High leverage and below-average size factor add financial risk.
Investment themes with ATEC
Devices and instruments for medical treatment
Services and products for aging population
Earnings Call · Q1 2024 · Mgmt. Guidance
Transcript signals
Bull points
- 138 million in total revenue, which is a 27% revenue growth, 450 basis points of adjusted EBITDA expansion, 30% surgical revenue growth, and 23% surgical volume growth.
- we continue to invest in a market that is either apathetic or disrupted.
- we deployed $60 million to enable a growing sales team to serve an expanded surgical volume.
Bear points
- Free cash use totaled $70 million, with approximately $60 million of that deployed, as planned, into the inventory and instruments that support the expansion of our distribution footprint and the new product launches.